热门资讯> 正文

Harmony Biosciences与Lupin就Wakix仿制药上市达成协议

2025-06-05 22:54

Lupin can launch a generic version of Harmony Biosciences' (NASDAQ:HRMY) Wakix (pitolisant) in January 2030 under a settlement agreement.
The agreement resolves patent infringement litigation filed by Harmony against Lupin regarding its ANDA for generic Wakix, a treatment for excessive daytime sleepiness.
Harmony noted that it is currently working on new formulations of pitolisant with utility patents that could provide exclusivity through 2044.

More on Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. 2025 Q1 - Results - Earnings Call Presentation
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript
Harmony Biosciences: A Compelling Risk-Reward Opportunity
Harmony Biosciences projects $1B+ opportunity for WAKIX in narcolepsy by 2030
Harmony Biosciences Holdings, Inc. Q1 2025 Earnings Preview

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。